Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients

Published:2024-03 Issue:3 Volume:49 Page:102403
ISSN:0146-2806
Container-title:Current Problems in Cardiology
language:en
Short-container-title:Current Problems in Cardiology

Author:

Singh Sahib^ORCID,Garg Aakash,Tantry Udaya S.,Bliden Kevin,Gurbel Paul A.,Gulati Martha^ORCID

Publisher

Elsevier BV

Reference28 articles.

1. Heart Disease and Stroke Statistics-2023 update: a report from the American Heart Association;Tsao;Circulation,2023

2. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

3. Cardiovascular outcomes trials for weight loss interventions: another tool for Cardiovascular prevention?;Neeland;Circulation,2021

4. Glucagon-like peptide 1 receptor agonists for type 2 diabetes;Hinnen;Diabetes Spectr,2017

5. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes;Marx;Circulation,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Achieving equitable access to incretin-based therapies in cardiovascular care;American Heart Journal Plus: Cardiology Research and Practice;2024-10

2. Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2024-09-11

3. Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis;Advances in Therapy;2024-08-14

4. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials;Clinical Cardiology;2024-07

5. Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists;The Journal of Clinical Pharmacology;2024-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3